120 related articles for article (PubMed ID: 32203205)
21. Investigating the effect of 28 BRCA1 and BRCA2 mutations on their related transcribed mRNA.
Quiles F; Menéndez M; Tornero E; del Valle J; Teulé À; Palanca S; Izquierdo A; Gómez C; Campos O; Santamaria R; Brunet J; Capellá G; Feliubadaló L; Lázaro C
Breast Cancer Res Treat; 2016 Jan; 155(2):253-60. PubMed ID: 26780556
[TBL] [Abstract][Full Text] [Related]
22. Additional molecular and clinical evidence open the way to definitive IARC classification of the BRCA1 c.5332G > A (p.Asp1778Asn) variant.
Minucci A; Lalle M; De Leo R; Mazzuccato G; Scambia G; Urbani A; Fagotti A; Concolino P; Capoluongo E
Clin Biochem; 2019 Jan; 63():54-58. PubMed ID: 30315757
[TBL] [Abstract][Full Text] [Related]
23. A tandem duplication of BRCA1 exons 1-19 through DHX8 exon 2 in four families with hereditary breast and ovarian cancer syndrome.
Du C; Mark D; Wappenschmidt B; Böckmann B; Pabst B; Chan S; Cao H; Morlot S; Scholz C; Auber B; Rhiem K; Schmutzler R; Illig T; Schlegelberger B; Steinemann D
Breast Cancer Res Treat; 2018 Dec; 172(3):561-569. PubMed ID: 30191368
[TBL] [Abstract][Full Text] [Related]
24. Frequency of mutations in BRCA genes and other candidate genes in high-risk probands or probands with breast or ovarian cancer in the Czech Republic.
Riedlova P; Janoutova J; Hermanova B
Mol Biol Rep; 2020 Apr; 47(4):2763-2769. PubMed ID: 32180084
[TBL] [Abstract][Full Text] [Related]
25. Assessment of the functional impact of germline BRCA1/2 variants located in non-coding regions in families with breast and/or ovarian cancer predisposition.
Dos Santos ES; Caputo SM; Castera L; Gendrot M; Briaux A; Breault M; Krieger S; Rogan PK; Mucaki EJ; Burke LJ; ; Bièche I; Houdayer C; Vaur D; Stoppa-Lyonnet D; Brown MA; Lallemand F; Rouleau E
Breast Cancer Res Treat; 2018 Apr; 168(2):311-325. PubMed ID: 29236234
[TBL] [Abstract][Full Text] [Related]
26. Common genetic variants contribute to incomplete penetrance: evidence from cancer-free BRCA1 mutation carriers.
Downs B; Sherman S; Cui J; Kim YC; Snyder C; Christensen M; Luo J; Lynch H; Wang SM
Eur J Cancer; 2019 Jan; 107():68-78. PubMed ID: 30551077
[TBL] [Abstract][Full Text] [Related]
27. In silico, in vitro and case-control analyses as an effective combination for analyzing BRCA1 and BRCA2 unclassified variants in a population-based sample.
Rodríguez-Balada M; Roig B; Martorell L; Melé M; Salvat M; Vilella E; Borràs J; Gumà J
Cancer Genet; 2016 Nov; 209(11):487-492. PubMed ID: 27886673
[TBL] [Abstract][Full Text] [Related]
28. Identifying sequence variants contributing to hereditary breast and ovarian cancer in BRCA1 and BRCA2 negative breast and ovarian cancer patients.
Jarhelle E; Riise Stensland HMF; Hansen GÅM; Skarsfjord S; Jonsrud C; Ingebrigtsen M; Strømsvik N; Van Ghelue M
Sci Rep; 2019 Dec; 9(1):19986. PubMed ID: 31882575
[TBL] [Abstract][Full Text] [Related]
29. Screening of BRCA1/2 genes mutations and copy number variations in patients with high risk for hereditary breast and ovarian cancer syndrome (HBOC).
El Ansari FZ; Jouali F; Marchoudi N; Bennani MM; Ghailani NN; Barakat A; Fekkak J
BMC Cancer; 2020 Aug; 20(1):747. PubMed ID: 32778078
[TBL] [Abstract][Full Text] [Related]
30. The c.5242C>A BRCA1 missense variant induces exon skipping by increasing splicing repressors binding.
Millevoi S; Bernat S; Telly D; Fouque F; Gladieff L; Favre G; Vagner S; Toulas C
Breast Cancer Res Treat; 2010 Apr; 120(2):391-9. PubMed ID: 19404736
[TBL] [Abstract][Full Text] [Related]
31. Mutation screening of TP53, CHEK2 and BRCA genes in patients at high risk for hereditary breast and ovarian cancer (HBOC) in Brazil.
Cipriano NM; de Brito AM; de Oliveira ES; de Faria FC; Lemos S; Rodrigues AN; de Oliveira Lopes D; Dos Santos LL
Breast Cancer; 2019 May; 26(3):397-405. PubMed ID: 30535581
[TBL] [Abstract][Full Text] [Related]
32. The identification of pathogenic variants in BRCA1/2 negative, high risk, hereditary breast and/or ovarian cancer patients: High frequency of FANCM pathogenic variants.
Schubert S; van Luttikhuizen JL; Auber B; Schmidt G; Hofmann W; Penkert J; Davenport CF; Hille-Betz U; Wendeburg L; Bublitz J; Tauscher M; Hackmann K; Schröck E; Scholz C; Wallaschek H; Schlegelberger B; Illig T; Steinemann D
Int J Cancer; 2019 Jun; 144(11):2683-2694. PubMed ID: 30426508
[TBL] [Abstract][Full Text] [Related]
33. Mis-splicing in breast cancer: identification of pathogenic BRCA2 variants by systematic minigene assays.
Fraile-Bethencourt E; Valenzuela-Palomo A; Díez-Gómez B; Goina E; Acedo A; Buratti E; Velasco EA
J Pathol; 2019 Aug; 248(4):409-420. PubMed ID: 30883759
[TBL] [Abstract][Full Text] [Related]
34. Prioritizing Variants in Complete Hereditary Breast and Ovarian Cancer Genes in Patients Lacking Known BRCA Mutations.
Caminsky NG; Mucaki EJ; Perri AM; Lu R; Knoll JH; Rogan PK
Hum Mutat; 2016 Jul; 37(7):640-52. PubMed ID: 26898890
[TBL] [Abstract][Full Text] [Related]
35. Combined annotation-dependent depletion score for BRCA1/2 variants in patients with breast and/or ovarian cancer.
Nakagomi H; Mochizuki H; Inoue M; Hirotsu Y; Amemiya K; Sakamoto I; Nakagomi S; Kubota T; Omata M
Cancer Sci; 2018 Feb; 109(2):453-461. PubMed ID: 29215753
[TBL] [Abstract][Full Text] [Related]
36. Pathogenicity evaluation of BRCA1 and BRCA2 unclassified variants identified in Portuguese breast/ovarian cancer families.
Santos C; Peixoto A; Rocha P; Pinto P; Bizarro S; Pinheiro M; Pinto C; Henrique R; Teixeira MR
J Mol Diagn; 2014 May; 16(3):324-34. PubMed ID: 24607278
[TBL] [Abstract][Full Text] [Related]
37. A dominant RAD51C pathogenic splicing variant predisposes to breast and ovarian cancer in the Newfoundland population due to founder effect.
Dawson LM; Smith KN; Werdyani S; Ndikumana R; Penney C; Wiede LL; Smith KL; Pater JA; MacMillan A; Green J; Drover S; Young TL; O'Rielly DD
Mol Genet Genomic Med; 2020 Feb; 8(2):e1070. PubMed ID: 31782267
[TBL] [Abstract][Full Text] [Related]
38. A specific GFP expression assay, penetrance estimate, and histological assessment for a putative splice site mutation in BRCA1.
Southey MC; Tesoriero A; Young MA; Holloway AJ; Jenkins MA; Whitty J; Misfud S; kConFab ; McLachlan SA; Venter DJ; Armes JE
Hum Mutat; 2003 Jul; 22(1):86-91. PubMed ID: 12815598
[TBL] [Abstract][Full Text] [Related]
39. A novel BRCA2 splice variant identified in a young woman.
Nicolussi A; Belardinilli F; Ottini L; Petroni M; Capalbo C; Giannini G; Coppa A
Mol Genet Genomic Med; 2020 Dec; 8(12):e1513. PubMed ID: 33159495
[TBL] [Abstract][Full Text] [Related]
40. Hereditary Breast and Ovarian Cancer Syndrome: Moving Beyond BRCA1 and BRCA2.
Hoang LN; Gilks BC
Adv Anat Pathol; 2018 Mar; 25(2):85-95. PubMed ID: 28914618
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
